Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | PAICS | P22234 | 2/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16899134 | 0.80 | IRAK4 (0.39) | IRAK4PAICS | |
| SCHEMBL16899135 | 0.80 | IRAK4 (0.39) | IRAK4PAICS | |
| Hydrochloric Acid SCHEMBL16899248 | 0.78 | IRAK4 (0.37) | IRAK4IRAK1 | |
| SCHEMBL16899066 | 0.78 | IRAK4 (0.54) | IRAK4IRAK1 | |
| SCHEMBL20879664 | 0.76 | KDM5B (0.43) | IRAK4RXRARXRBRXRGMCL1 | |
| SCHEMBL16896617 | 0.75 | KDM5B (0.42) | IRAK4RXRARXRBRXRGMCL1 | |
| SCHEMBL16896604 | 0.73 | KDM5B (0.40) | RXRARXRBRXRGMCL1KDM5B | |
| SCHEMBL16899063 | 0.73 | CLK2 (0.47) | IRAK4MCL1 | |
| SCHEMBL16899229 | 0.72 | IRAK4 (0.52) | IRAK4 | |
| SCHEMBL20801240 | 0.72 | IRAK4 (0.43) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092226-B1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2019-03-13 | — | — | EP | disclosed |
| US-10160753-B2 | Indazole compounds as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-12-25 | — | — | US | disclosed |
| EP-3092226-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| WO-2015104662-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160753-B2 | Indazole compounds as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885RXRA 2262/4885RXRB 2143/4885 |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885RXRA 2262/4885RXRB 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.